A multi-year, multi-institutional, collaborative program led by Ethos Discovery that will build on the success of the Ethos CHAMP study and now seeks to deliver a curative outcome for dogs with hemangiosarcoma using molecular medicine and advanced clinical research strategies. Initial clinical and scientific collaborators and fundraising for ePUSH has begun.
The unique combination of molecular biology and drug discovery strengths that exist within Ethos Discovery taught us that hemangiosarcoma is not a single cancer, but rather at least 4 cancers, characterized by distinct genomic alterations. From our unique perspective as both molecular biologists and veterinary Oncologists, we view these distinct cancer entities through the optics of novel therapeutics that may be reasonably applied to the identified disease subsets, rather than an academic plot of mutated genes.
In addition, preliminary data from our team has demonstrated the presence of mutated cancer DNA in the blood of dogs with these cancers (i.e. liquid biopsy). Collectively these new data and the success of our team allows us now to deliver a highly advanced clinical trial program in the field of precision medicine that will seek to deliver curative outcomes for this disease through an umbrella study design. An umbrella study matches specific patients with molecular subsets of this disease with specific therapeutics that target genomic alterations of that patient subset. Collectively this future of cancer medicine is referred to as Precision Medicine. Our understanding of highly favorable surgical and perioperative care of patients will further fuel the necessary accrual of patients with splenic hemangiosarcoma to the planned umbrella study of 400 dogs over approximately 5 years. Novel correlative studies, including detection of mutated tumor DNA in the blood of dogs with hemangiosarcoma, will accelerate the completion of the planned trials through a “fail early” adaptive trial design and potentially through drug matching of blood DNA.
- To be decided